BRIEF-Stoke Therapeutics Announces Completion Of Enrollment Of 162 Patients Into The Phase 3 Emperor Study Of Zorevunersen, An Investigational Medicine For The Treatment Of Dravet Syndrome

Stoke Therapeutics

Stoke Therapeutics

STOK

0.00

June 30 (Reuters) - Stoke Therapeutics Inc STOK.O:

  • STOKE THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF 162 PATIENTS INTO THE PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME

  • STOKE THERAPEUTICS - PLANS TO INITIATE ROLLING U.S. NDA SUBMISSION TO FDA IN Q1 2027

  • STOKE THERAPEUTICS - PHASE 3 DATA READOUT ANTICIPATED IN Q3 2027, TO COMPLETE NDA SUBMISSION IN H2 2027

  • STOKE THERAPEUTICS - NO PATIENTS HAVE DISCONTINUED TREATMENT IN PHASE 3 EMPEROR STUDY

Source text: ID:nBw5pdyvXa

Further company coverage: STOK.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.